Literature DB >> 15312165

Differential regulation of dopamine D1 and D2 signaling by nicotine in neostriatal neurons.

Miho Hamada1, Hideho Higashi, Angus C Nairn, Paul Greengard, Akinori Nishi.   

Abstract

Nicotine, acting on nicotinic acetylcholine receptors (nAChRs) expressed at pre-synaptic dopaminergic terminals, has been shown to stimulate the release of dopamine in the neostriatum. However, the molecular consequences of pre-synaptic nAChR activation in post-synaptic neostriatal neurons are not clearly understood. Here, we investigated the effect of nAChR activation on dopaminergic signaling in medium spiny neurons by measuring phosphorylated DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa) at Thr34 (the PKA-site) in mouse neostriatal slices. Nicotine produced dose-dependent responses, with a low concentration (1 microm) causing a sustained decrease in DARPP-32 Thr34 phosphorylation and a high concentration (100 microm) causing a transient increase in DARPP-32 Thr34 phosphorylation. Depending on the concentration of nicotine, either dopamine D2 or D1 receptor signaling was predominantly activated. Nicotine at a low concentration (1 microm) activated dopamine D2 receptor signaling in striatopallidal/indirect pathway neurons, likely by activating alpha4beta2* nAChRs at dopaminergic terminals. Nicotine at a high concentration (100 microm) activated dopamine D1 receptor signaling in striatonigral/direct pathway neurons, likely by activating (i) alpha4beta2* nAChRs at dopaminergic terminals and (ii) alpha7 nAChRs at glutamatergic terminals, which, by stimulating the release of glutamate, activated NMDA/AMPA receptors at dopaminergic terminals. The differential effects of low and high nicotine concentrations on D2- and D1-dependent signaling pathways in striatal neurons may contribute to dose-dependent actions of this drug of abuse. Copyright 2004 International Society for Neurochemistry

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312165     DOI: 10.1111/j.1471-4159.2004.02574.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  40 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  In vivo effects of the anatoxin-a on striatal dopamine release.

Authors:  F Campos; R Durán; L Vidal; L R F Faro; M Alfonso
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

3.  Mecamylamine attenuates cue-induced reinstatement of nicotine-seeking behavior in rats.

Authors:  Xiu Liu; Anthony R Caggiula; Susan K Yee; Hiroko Nobuta; Alan F Sved; Robert N Pechnick; Russell E Poland
Journal:  Neuropsychopharmacology       Date:  2006-06-21       Impact factor: 7.853

Review 4.  Protein kinases and addiction.

Authors:  Anna M Lee; Robert O Messing
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

5.  Nicotine improves probabilistic reward learning in wildtype but not alpha7 nAChR null mutants, yet alpha7 nAChR agonists do not improve probabilistic learning.

Authors:  Morgane Milienne-Petiot; Kerin K Higa; Andrea Grim; Debbie Deben; Lucianne Groenink; Elizabeth W Twamley; Mark A Geyer; Jared W Young
Journal:  Eur Neuropsychopharmacol       Date:  2018-09-11       Impact factor: 4.600

6.  Effects of nicotine administration on striatal dopamine signaling after traumatic brain injury in rats.

Authors:  Samuel S Shin; Eric R Bray; C Edward Dixon
Journal:  J Neurotrauma       Date:  2011-10-24       Impact factor: 5.269

7.  Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens.

Authors:  Arthur L Brody; Mark A Mandelkern; Richard E Olmstead; David Scheibal; Emily Hahn; Sharon Shiraga; Eleanor Zamora-Paja; Judah Farahi; Sanjaya Saxena; Edythe D London; James T McCracken
Journal:  Arch Gen Psychiatry       Date:  2006-07

8.  Chronic treatment with galantamine rescues reversal learning in an attentional set-shifting test after experimental brain trauma.

Authors:  Ihuoma Njoku; Hannah L Radabaugh; Melissa A Nicholas; Lindsay A Kutash; Darik A O'Neil; Ian P Marshall; Jeffrey P Cheng; Anthony E Kline; Corina O Bondi
Journal:  Exp Neurol       Date:  2019-01-31       Impact factor: 5.330

Review 9.  Preclinical Models to Investigate Mechanisms of Negative Symptoms in Schizophrenia.

Authors:  Samuel A Barnes; Andre Der-Avakian; Jared W Young
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

10.  Regional heterogeneity of nicotine effects on neurotransmitters in rat brains in vivo at low doses.

Authors:  S Rossi; S Singer; E Shearman; H Sershen; A Lajtha
Journal:  Neurochem Res       Date:  2005-01       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.